Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of 5-dose vs 4-dose schedules of lyophilized human rabies vaccine (Vero cells) in healthy people aged 10–50 years
ChiCTR2200061926Phase 3Not yet recruiting
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Purified Vero cell rabies vaccine in rabies (3 arms), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Positive conversion of antibody and Geometric Mean Concentration of rabies antibodies. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
Purified Vero cell rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2200061926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061926.